Navigation Links
New drug candidate prolongs the lives of pancreatic cancer patients
Date:7/20/2009

t study, researchers tested for both toxicity and effectiveness. They gave 19 patients with advanced pancreatic cancer daily doses of salirasib along with a standard gemcitabine regimen. Salirasib was well tolerated by the patients, and they surpassed on average the number of months they would have lived on gentamiacine alone. There were no toxic side effects, such as heart or lung ailments. Tumor biopsies showed a significant reduction in Ras levels, suggesting that the drug is inhibiting the action of Ras in the tumor itself.

For this study, Salirasib was licensed by Concordia Pharmaceuticals, which collaborated with the Memorial Sloan Kettering Cancer Center, Johns Hopkins, the M.D. Anderson Cancer Center and other institutes in the United States.

If Phase II/III trials are successful, Prof. Kloog's drug will be the first successful Ras antagonist known to medical science. Salirabib could be medically available in as little as two years.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Some Epilepsy Patients Are Good Candidates for Surgery
2. Presidential Candidates Address Health, Financial Security at AARPs Life@50+
3. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
4. U.S. Physicians Question Presidential Candidates
5. Schizophrenia candidate genes affect even healthy individuals
6. Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
7. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
8. Poll Shows Voters Want Long Term Care Included in Presidential Candidates Healthcare Proposals, Released at 2007 National Long Term Care Symposium
9. 1 in 5 bariatric surgery candidates not psychologically cleared for surgery
10. Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates
11. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... John DeLuca, PhD, and Yael Goverover, PhD, OT, have ... persons with multiple sclerosis (MS) perform everyday life tasks. ... Measure Everyday Life Functional Activity in Multiple Sclerosis" provides ... senior VP of Research & Training at Kessler Foundation. ... is a visiting scientist at Kessler Foundation. She was ...
(Date:4/14/2014)... the answer to one open-ended question predicted the teenagers, offending ... think you,ll live?", According to the study, having little hope ... Piquero said the study found those who don,t view a ... rates and commit more serious offenses, while those who believe ... less., "In a lot of distressed communities and for a ...
(Date:4/14/2014)... A new study identifies a molecule that is ... that the molecule could be an important target for ... progression. , The study of microRNA-135b (miR-135b) in two ... journal Cancer Cell and was led by ... Arthur G. James Cancer Hospital and Richard J. ...
(Date:4/14/2014)... CHICAGO --- Depression can hit young fathers hard -- with ... of their children,s lives, a new Northwestern Medicine study has ... over the first five years of fatherhood for these young ... fathers and whom lived in the same home as their ... in the journal Pediatrics . , This study is ...
(Date:4/14/2014)... around the world, many people live and work in ... block sunlight. And as the global population continues to ... will only spread. , To alleviate the problem, ... redirects sunlight onto narrow streets and alleyways. The panel ... at an angle, where it spreads sunlight onto the ...
Breaking Medicine News(10 mins):Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Study identifies a likely key driver of colorectal cancer development and progression 2Health News:Young dads at high risk of depression, too 2Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2
... Inc. and Schering-Plough Corporation (NYSE: SGP) today announced ... new indication for REMICADE(R) (infliximab) allowing for the ... pediatric patients aged 6 to 17 years, who ... corticosteroid, an immunomodulator and primary nutrition therapy, or ...
... known as marijuana or ganja, can help in the ... when body tissues are attacked by its own immune ... the University of Bonn, used tetrahydrocannabinol (THC), the active ... found that it reduced skin allergies. ,However, ...
... been eradicated in Europe but new infections and drug resistant ... Thursday in Stockholm showed . "The public health systems in ... well protected but there is no room for complacency," Zsuzsanna ... Control (ECDC), said at a press conference. ,According ...
... among asylum seekers in Denmark has proportionally tripled since 2001 ... a study published Thursday . ,Sixty-seven asylum seekers ... percent of the total -- tried to end their lives ... to Help Refugees said. ,That contrasted with the ...
... found that that umbilical cord blood transplants may provide ... patients . ,The study was conducted by a ... the University of Minnesota. ,As part of ... patients who received unrelated bone marrow transplants with the ...
... Brazil, China, South Africa and Mexico-- which form 42 ... united front on the issue of climate change ... leaders. ,In a joint statement released after ... Silva of Brazil, Chinese President Hu Jintao, Indian Prime ...
Cached Medicine News:Health News:Remicade(R) Get Approval for First and Only Biologic Treatment for Pediatric Crohn's Disease 2Health News:Cord Blood Yields Better Results Than Bone Marrow Transplant for Cancer Patients 2
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ... biology, human genetics, genomic technology, and drug discovery ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014 /PRNewswire/ ... "Lifetime in Dermatology Achievement Award" from the Journal ... Orlando Dermatology Aesthetic & Clinical Conference (ODAC). The event ... in Florida . ... comprehensive report on the practice of dermatology for clinical ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of ... able to protect their most important business ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Device Industry, it steadfastly remains one of ... involving IP infringement. This litigious nature can ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... Inc. magazine has ranked Universal SmartComp #503 ... fourth annual Inc. 5000, an exclusive ranking of the ... comprehensive look at the most important segment of the ... 7-Eleven, Brooklyn Brewery, and Radio Flyer, maker of the ...
... SILVER SPRING, Md., Sept. 24 The U.S. ... an estrogen/progestin combined oral contraceptive that also contains ... (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) (Logo: ... a metabolite of folic acid, a water-soluble B-vitamin ...
Cached Medicine Technology:Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 2Universal SmartComp Ranks No. 503 Overall and No. 35 in the Health Sector on the 2010 Inc. 5000 with Three-Year Sales Growth of 600% 3FDA Approves Combination Contraceptive Containing a Folate 2
Universal Hub with Varying Blade Edge Diameters For Mounting the Blade to the Handle; Stainless Steel....
2 Sided Pivoted Closed Ring Design,Pointed And Smooth Sides; in stainless steel....
Blunt Tapered Tip in stainless steel....
... meet the high-quality and ... practices. The optional Profile ... accessory features a unique ... increases the accuracy of ...
Medicine Products: